Shares of XBiotech Inc. (NASDAQ:XBIT) shot up 1.9% on Thursday . The stock traded as high as $15.15 and last traded at $14.78, with a volume of 544,058 shares changing hands. The stock had previously closed at $14.50.

A number of equities analysts recently commented on the stock. Noble Financial reiterated a “buy” rating and issued a $24.00 target price on shares of XBiotech in a research report on Thursday, May 19th. Zacks Investment Research upgraded shares of XBiotech from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Tuesday, May 24th.

The firm’s market cap is $478.13 million. The company has a 50-day moving average price of $16.63 and a 200 day moving average price of $11.58.

In other XBiotech news, Director W Thorpe Mckenzie bought 20,000 shares of XBiotech stock in a transaction on Thursday, May 26th. The stock was acquired at an average cost of $13.96 per share, with a total value of $279,200.00. Following the completion of the acquisition, the director now owns 3,898,600 shares in the company, valued at $54,424,456. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. The Company primarily focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.